MR imaging of Crohn disease: use of perflubron as a gastrointestinal contrast agent.
This study was undertaken to evaluate the use of perflubron (perfluorooctylbromide) as an oral contrast agent for magnetic resonance (MR) imaging of patients with Crohn disease. MR examinations were performed before and after perflubron administration in 12 patients with documented Crohn disease. Glucagon was administered intramuscularly before the post-perflubron examinations. Each patient also underwent abdominal computed tomography within 48 hours of MR imaging. The imaging studies were analyzed for effectiveness of bowel marking with oral contrast agent, clarity bowel wall visualization, and presence of bowel wall thickening and extraluminal manifestations of Crohn disease such as abscess or fistula formation. Analysis of the imaging studies showed effective marking of the bowel with perflubron and improved bowel wall visualization on postcontrast MR images. Detection of bowel wall thickening and extraluminal complications of Crohn disease was not significantly improved on postcontrast MR images. The authors conclude that perflubron administration effectively marked the bowel and increased the clarity of bowel wall visualization but did not significantly increase the detection of abnormalities related to Crohn disease in the study population.
Anderson
C M
CM
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO 63110.
Brown
J J
JJ
Balfe
D M
DM
Heiken
J P
JP
Borrello
J A
JA
Clouse
R E
RE
Pilgram
T K
TK
D000328:Adult; D003287:Contrast Media; D003424:Crohn Disease / Q000175:diagnosis*; D005260:Female; D005466:Fluorocarbons; D005934:Glucagon; D006801:Humans; D006842:Hydrocarbons, Brominated; D007082:Ileum / Q000473:pathology; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D014057:Tomography, X-Ray Computed
D003287:Contrast Media; D005466:Fluorocarbons; D006842:Hydrocarbons, Brominated; D005934:Glucagon; C003072:perflubron